Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the study is to explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP (non-activated B-cell) or R2-CHOP (activated B-cell) followed by durvalumab consolidation therapy in previously untreated subjects diagnosed with high-risk DLBCL.
Inclusion criteria
- Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)